Biotechnology

,

Biotechnology Australia

,

Australian Biotechnology

,

Biotech

,

Australian Biotech

, Australian Business Directory, Business Directory Online

Transdermal Drug Delivery

The combination of the ACROSS?, MDTS? and Patchless Patch? delivery method, with medically approved drugs form the basis of Acrux's pharmaceutical businesses business (US Patent 6,299,900; PCT filed Feb 19, 1997). The application of the technology will be suitable for existing Off-Patent Drugs as well as new drugs patented by the Group's partners.

ACROSS? penetration enhancers: These enhancers are small, lipid-like compounds which allow drugs to pass through the skin. They are commonly used safe, non-irritant sunscreen materials whose utility for drug transport to and through the skin was discovered by scientists at Monash University’s Victorian College of Pharmacy.

Metered Dose Transdermal System (The MDTS?): is placed gently against the skin and depressed releasing a light spray which quickly dries on the skin. The ACROSS? enhancers allow drugs to pass through the top layers of the skin. A once a day application typically delivers consistent amounts through the skin to the blood stream.

Patchless Patch™ delivery method based on application of a rapid-drying metered-dose of solution to the skin. This forms a reservoir of drug and enhancer within the skin, from which drug is released into the bloodstream in a sustained manner.

These methods can be used for symptoms of menopause, femalel androgen insufficiency, severe pain, central nervous system disorders, male androgen insufficiency, urinary incontinence, contraception and smoking cessation.

Acrux Limited

This biotech innovation has been closely associated with this biotechnology company.

Home  |  Timeline  |  Innovations  |  Companies  |  Scientists  |  Sponsors  |  Contact Us  |   Site Archive
Page Archive  |  University Archive  |  News Channel  |  Blog Archive  |  Forum Archive  |  eCommerce Archive